Barry Burgdorf

Hogan Lovells

+ Follow Contact

Latest Posts › Venture Capital

Share:

JPM panelists see opportunities under new U.S. regulators for venture capital and investing in emerging life sciences fields

The outcome of the 2024 U.S. election had far-reaching implications for the global investment landscape, especially in the dynamic field of venture capital and early-stage investing. Speaking at the J.P. Morgan Healthcare...more

2/3/2025 / Biotechnology , Department of Health and Human Services (HHS) , Food and Drug Administration (FDA) , Investors , Life Sciences , Pharmaceutical Industry , Public Health , Venture Capital

JPM2023 Trendspotting: funding and early valuation

As the industry readies itself for the January 2023 pilgrimage to the J.P. Morgan Healthcare Conference (JPM) and Biotech Showcase in San Francisco, our market-leading life sciences and health care industry team has prepared...more

12/7/2022 / Capital Raising , Emerging Technology Companies , Intellectual Property Protection , Investigational New Drug Application (IND) , Life Sciences , Strategic Planning , Valuation , Venture Capital

World Stem Cell Summit offers guidance on positioning your regenerative medicine start-up for success

Speaking at the World Stem Cell Summit hosted by the Regenerative Medicine Foundation, Hogan Lovells partners Andrew Strong and Barry Burgdorf provided best practices for launching a start-up biotech company in the cell,...more

7/7/2022 / Biotechnology , Life Sciences , Pharmaceutical Industry , Research and Development , Venture Capital

3 Results

View per page

Page: of 1